Summary
The Valporate Safety Implementation Group (VSIG) is a clinically-led group set up to help facilitate the reduction of the use of sodium valporate in women and girls where there is a safer alternative.
Content
Sodium valporate carries a number of risks to the health of a developing fetus such as birth defects and problems with development and learning. The VSIG are working to reduce usage by 50% by 2023 and are supporting the implementation of the recommendations of the Independent Medicines and Medical Devices Safety (IMMDS) Review, published in July 2020.
Recommended Comments
Create an account or sign in to comment